Insider trading

Period: 120 months Stock: ARWR Minimum amount: $100K × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

180 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

180 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

180 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

180 decisions over 120 months Remove this filter
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
180 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
180 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

180 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
18 Aug 2026
PERRY MICHAEL S Director
Sold at will
$1.01M 11,600 at 87.30
9.4%
Not planned
18 Aug 2026
Sold at will
$173.92K 2,000 at 86.96
6.0%
Not planned
12 May 2026
Lu Hongbo Director
Sold on a plan
$228.33K 2,970 at 76.88
5.4%
Planned (10b5-1)
23 Apr 2026
Hamilton James C Chief Medical Officer
Sold on a plan
$750.00K 10,000 at 75.00
4.2%
Planned (10b5-1)
22 Apr 2026
Apel Daniel Joseph Chief Financial Officer
Sold on a plan 3×
$934.29K 13,095 at 71.35
7.4%
Planned (10b5-1)
5 Mar 2026
Hamilton James C Chief Medical Officer
Sold on a plan
$641.90K 10,000 at 64.19
4.0%
Planned (10b5-1)
5 Jan 2026
Sold on a plan 12×
$3.12M 49,493 at 63.11
9.4%
Planned (10b5-1)
5 Jan 2026
Hamilton James C Chief Medical Officer
Sold on a plan 7×
$2.53M 40,164 at 63.11
18.9%
Planned (10b5-1)
2 Jan 2026
Anzalone Christopher Richard Chief Executive Officer
Sold on a plan 2×
$871.70K 13,187 at 66.10
0.3%
Planned (10b5-1)
29 Dec 2025
Anzalone Christopher Richard Chief Executive Officer
Sold on a plan 2×
$3.58M 51,726 at 69.13
1.3%
Planned (10b5-1)
26 Dec 2025
Ferrari Mauro Director
Sold on a plan
$527.10K 7,530 at 70.00
9.8%
Planned (10b5-1)
22 Dec 2025
Anzalone Christopher Richard Chief Executive Officer
Sold on a plan 2×
$861.34K 12,586 at 68.44
0.3%
Planned (10b5-1)
19 Dec 2025
Anzalone Christopher Richard Chief Executive Officer
Sold on a plan 3×
$909.68K 13,445 at 67.66
0.4%
Planned (10b5-1)
19 Dec 2025
Sold on a plan 3×
$679.49K 10,040 at 67.68
21.9%
Planned (10b5-1)
19 Dec 2025
Sold on a plan 3×
$676.62K 10,000 at 67.66
22.9%
Planned (10b5-1)
19 Dec 2025
Sold on a plan 3×
$566.04K 8,367 at 67.65
12.9%
Planned (10b5-1)
17 Dec 2025
Anzalone Christopher Richard Chief Executive Officer
Sold at will 4×
$5.44M 85,000 at 64.04
2.2%
Not planned
16 Dec 2025
Anzalone Christopher Richard Chief Executive Officer
Sold at will 9×
$3.40M 54,298 at 62.58
1.4%
Not planned
15 Dec 2025
Anzalone Christopher Richard Chief Executive Officer
Sold at will 3×
$8.95M 130,000 at 68.85
3.2%
Not planned
5 Dec 2025
PERRY MICHAEL S Director
Sold at will
$991.74K 16,250 at 61.03
12.4%
Not planned
28 Nov 2025
Ferrari Mauro Director
Sold at will
$493.41K 8,750 at 56.39
11.3%
Not planned
1 Oct 2025
Hamilton James C Chief Medical Officer
Sold on a plan
$700.00K 20,000 at 35.00
8.6%
Planned (10b5-1)
12 Sep 2025
Hamilton James C Chief Medical Officer
Sold on a plan
$450.00K 15,000 at 30.00
6.1%
Planned (10b5-1)
2 Sep 2025
Hamilton James C Chief Medical Officer
Sold on a plan
$375.00K 15,000 at 25.00
5.7%
Planned (10b5-1)
15 Aug 2025
Hamilton James C Chief Medical Officer
Sold on a plan
$187.78K 9,389 at 20.00
3.5%
Planned (10b5-1)
11 Apr 2025
Anzalone Christopher Richard Chief Executive Officer
Sold at will
$583.69K 50,800 at 11.49
1.3%
Not planned
10 Apr 2025
Anzalone Christopher Richard Chief Executive Officer
Sold at will
$543.50K 50,000 at 10.87
1.2%
Not planned
9 Apr 2025
Anzalone Christopher Richard Chief Executive Officer
Sold at will 3×
$406.14K 40,322 at 10.07
1.0%
Not planned
13 Mar 2025
Anzalone Christopher Richard Chief Executive Officer
Sold at will
$774.97K 51,425 at 15.07
1.3%
Not planned
4 Mar 2025
Anzalone Christopher Richard Chief Executive Officer
Sold on a plan
$2.27M 133,333 at 17.02
3.4%
Planned (10b5-1)
3 Mar 2025
Anzalone Christopher Richard Chief Executive Officer
Sold on a plan
$3.01M 166,667 at 18.03
4.1%
Planned (10b5-1)
7 Jan 2025
Myszkowski Kenneth Allen Chief Financial Officer
Sold on a plan 2×
$354.50K 18,000 at 19.69
3.8%
Planned (10b5-1)
7 Jan 2025
O'Brien Patrick COO and General Counsel
Sold on a plan
$157.52K 8,000 at 19.69
1.5%
Planned (10b5-1)
6 Jan 2025
Hamilton James C Chief Discovery/Trans Medicine
Sold on a plan 2×
$648.82K 32,729 at 19.82
10.7%
Planned (10b5-1)
6 Jan 2025
O'Brien Patrick COO and General Counsel
Sold on a plan 2×
$578.54K 29,184 at 19.82
5.2%
Planned (10b5-1)
6 Jan 2025
Myszkowski Kenneth Allen Chief Financial Officer
Sold on a plan 2×
$538.60K 27,167 at 19.83
5.4%
Planned (10b5-1)
2 Jan 2025
Anzalone Christopher Richard Chief Executive Officer
Sold on a plan
$219.46K 11,520 at 19.05
0.3%
Planned (10b5-1)
23 Dec 2024
Anzalone Christopher Richard Chief Executive Officer
Sold on a plan
$246.11K 12,563 at 19.59
0.3%
Planned (10b5-1)
18 Dec 2024
Anzalone Christopher Richard Chief Executive Officer
Sold on a plan 3×
$567.49K 26,712 at 21.24
0.7%
Planned (10b5-1)
16 Dec 2024
Sold on a plan
$197.06K 8,994 at 21.91
29.8%
Planned (10b5-1)
16 Dec 2024
GIVEN DOUGLAS B Director
Sold on a plan
$109.50K 5,000 at 21.90
3.9%
Planned (10b5-1)
2 Jul 2024
Oliver Tracie Chief Commercial Officer
Sold on a plan
$237.48K 9,394 at 25.28
6.9%
Planned (10b5-1)
1 Apr 2024
Hamilton James C Chief Discovery/Trans Medicine
Sold at will
$168.18K 6,000 at 28.03
2.8%
Not planned
6 Mar 2024
Myszkowski Kenneth Allen Chief Financial Officer
Sold at will
$1.41M 40,000 at 35.19
9.1%
Not planned
31 Jan 2024
Anzalone Christopher Richard Chief Executive Officer
Sold on a plan 2×
$1.86M 57,499 at 32.35
1.5%
Planned (10b5-1)
12 Jan 2024
Hamilton James C Chief Discovery/Trans Medicine
Sold on a plan 2×
$292.90K 7,940 at 36.89
3.6%
Planned (10b5-1)
11 Jan 2024
Sold on a plan 2×
$179.81K 4,720 at 38.10
12.9%
Planned (10b5-1)
11 Jan 2024
Sold on a plan 2×
$149.76K 3,934 at 38.07
7.6%
Planned (10b5-1)
11 Jan 2024
Ferrari Mauro Director
Sold on a plan 2×
$119.79K 3,147 at 38.06
4.9%
Planned (10b5-1)
11 Jan 2024
GIVEN DOUGLAS B Director
Sold on a plan 2×
$110.79K 2,911 at 38.06
2.2%
Planned (10b5-1)
Showing 1–50 of 180. Page 1 of 4 Older →